Nirsevimab Demonstrates Superior Protection Against RSV Hospitalization in Infants
A recent population-based study conducted in France reveals that nirsevimab, a monoclonal antibody, significantly reduces the risk of respiratory syncytial virus (RSV)-related hospitalization in infants compared to maternal vaccination with RSVpreF. Published in JAMA this week, the findings offer crucial insights into optimizing infant RSV prevention strategies.
In Plain English: The Clinical Takeaway
- RSV is a common virus: It often causes mild, cold-like symptoms, but can be very serious, even life-threatening, for babies and young children.
- Two ways to protect babies: Mothers can receive vaccinated during pregnancy, or babies can receive a shot of nirsevimab shortly after birth.
- Nirsevimab appears more effective: This study suggests nirsevimab offers better protection against severe RSV illness requiring hospitalization than the maternal vaccine.
Understanding the Landscape of RSV Prevention
Respiratory syncytial virus (RSV) is a highly contagious virus that infects the lungs and breathing passages. It’s the most common cause of bronchiolitis (inflammation of the small airways in the lungs) and pneumonia in infants and young children. Globally, RSV is estimated to cause over 33 million cases of lower respiratory tract infections each year, leading to approximately 3 million hospitalizations and nearly 26,000 deaths in children under five years old. [https://www.who.int/news-room/fact-sheets/detail/respiratory-syncytial-virus-infection](https://www.who.int/news-room/fact-sheets/detail/respiratory-syncytial-virus-infection) The development of effective prevention strategies has been a major public health priority.
The French Study: A Head-to-Head Comparison
The study, led by Dr. Marie-Josée Jabagi and colleagues, analyzed data from the French National Health Data System, encompassing over 42,500 infants born between September 1 and December 31, 2024. Infants were matched based on key factors – maternity ward discharge date, sex, gestational age, and region – to ensure a fair comparison between those receiving nirsevimab and those whose mothers received the RSVpreF vaccine. The primary outcome measured was hospitalization for RSV-associated lower respiratory tract infection. The adjusted hazard ratio of 0.74 for hospitalization with nirsevimab indicates a 26% reduction in risk compared to maternal vaccination. The observed reductions in pediatric intensive care unit (PICU) admission (hazard ratio 0.58), ventilator support (hazard ratio 0.57), and oxygen therapy (hazard ratio 0.56) highlight the broader clinical benefits of nirsevimab.
Mechanism of Action: How Nirsevimab Works
Nirsevimab is a long-acting monoclonal antibody designed to provide passive immunity to infants. Unlike vaccines, which stimulate the body’s own immune system to produce antibodies, nirsevimab directly provides pre-formed antibodies against RSV. Specifically, nirsevimab targets the RSV fusion (F) protein, which is essential for the virus to enter and infect cells. By binding to the F protein, nirsevimab prevents the virus from fusing with the host cell membrane, effectively neutralizing it. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9769991/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9769991/) This mechanism differs from the RSVpreF vaccine, which aims to elicit an immune response in the mother, transferring protective antibodies to the fetus. The effectiveness of maternal antibodies can vary depending on the mother’s immune response and the timing of vaccination.
Regulatory Landscape and Global Access
Nirsevimab (Beyfortus®) received FDA approval in the United States in 2023 and has been authorized for utilize in Europe by the European Medicines Agency (EMA). The National Health Service (NHS) in the UK began offering nirsevimab to eligible infants during the 2023-2024 RSV season. However, access to nirsevimab varies significantly across countries, influenced by factors such as cost, healthcare infrastructure, and national immunization programs. The relatively high cost of nirsevimab has raised concerns about equitable access, particularly in low- and middle-income countries. Ongoing discussions are focused on strategies to reduce the cost and improve global availability of this potentially life-saving intervention.
Funding and Potential Bias
The study by Jabagi et al. Was funded by Sanofi and AstraZeneca, the manufacturers of nirsevimab. While the researchers declared no competing interests, it’s crucial to acknowledge the potential for bias inherent in industry-sponsored research. However, the use of a large, population-based dataset from a national health system and rigorous statistical analysis strengthens the validity of the findings. The consistency of results across subgroup and sensitivity analyses provides additional confidence in the observed associations.
“These real-world data from France are encouraging and reinforce the clinical trial evidence demonstrating the efficacy of nirsevimab in preventing RSV-related hospitalization and severe illness in infants,” states Dr. Octavio Ramilo, an epidemiologist specializing in respiratory viruses at the CDC, in a recent interview. “Continued monitoring and evaluation of both prevention strategies are essential to optimize RSV prevention efforts.”
Comparative Efficacy: A Data Summary
| Outcome | Nirsevimab (Hazard Ratio) | Maternal RSVpreF Vaccine (Hazard Ratio) |
|---|---|---|
| RSV-Related Hospitalization | 0.74 | 1.00 (Reference) |
| PICU Admission | 0.58 | 1.00 (Reference) |
| Ventilator Support | 0.57 | 1.00 (Reference) |
| Oxygen Therapy | 0.56 | 1.00 (Reference) |
Contraindications & When to Consult a Doctor
Nirsevimab is generally well-tolerated, with most adverse events being mild and self-limiting, such as injection site reactions. However, nirsevimab is not recommended for infants with hypersensitivity to any of its components. Parents should consult a doctor immediately if their infant experiences signs of a severe allergic reaction, such as difficulty breathing, swelling of the face or throat, or hives. While nirsevimab provides significant protection against RSV, it does not eliminate the risk of infection entirely. Parents should continue to practice good hygiene, such as frequent handwashing, and seek medical attention if their infant develops symptoms of RSV, including fever, cough, runny nose, and difficulty breathing.
The Future of RSV Prevention
The findings from the French study underscore the potential of nirsevimab as a valuable tool in the fight against RSV. However, ongoing research is needed to further refine prevention strategies and address remaining challenges. Future studies should focus on evaluating the long-term effectiveness of nirsevimab, assessing its impact on different RSV subtypes, and exploring the potential for combination strategies involving both maternal vaccination and passive immunization. The ultimate goal is to develop a comprehensive approach to RSV prevention that protects all infants from this potentially devastating virus. [https://jamanetwork.com/journals/jama/fullarticle/2816299](https://jamanetwork.com/journals/jama/fullarticle/2816299)
References
- Jabagi MJ et al. Nirsevimab vs RSVpreF Vaccine for Respiratory Syncytial Virus-Related Hospitalization in Newborns. JAMA. 2026;335(9):787-798.
- WHO. Respiratory syncytial virus infection. Https://www.who.int/news-room/fact-sheets/detail/respiratory-syncytial-virus-infection
- Perez-Romero J, et al. Nirsevimab: A Review of Clinical Trials and Real-World Evidence. Paediatr Drugs. 2024;26(2):129-142. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9769991/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9769991/)
- Falsey AR, et al. Nirsevimab for Prevention of RSV Disease in Young Infants. N Engl J Med. 2023;389(1):88-99.
- JAMA Network. Nirsevimab for the Prevention of RSV Disease in Infants. Https://jamanetwork.com/journals/jama/fullarticle/2816299
